http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102552949-B
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_421045189d9262db882b8be405d02961 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-10 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 |
filingDate | 2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c85d8e8f656c6be010a14fb6277cbc89 |
publicationDate | 2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-102552949-B |
titleOfInvention | 99mTc-labeled RGD (Arginine-Glycine-Aspartic acid) polypeptide tumor diagnosis medicament and preparation method thereof |
abstract | The invention relates to three RGD (Arginine-Glycine-Aspartic acid) polypeptide radioactive medicaments for positive tumor diagnosis of an intergrinalphavbeta3 receptor and preparation methods thereof. The three RGD polypeptide radioactive medicaments are structurally RGD annular dipolymers, and radioactive nuclein 99mTc labeling is performed through a dual-functional chelating agent. The medicaments are mainly characterized in that: a [K(NIC)] structure which is connected with RGD is used for replacing the conventional 99mTc-labeled synergistic ligand, i.e., trisodium salt of tri(m-sulfonphenyl) phosphine (TPPTS), so that the molecular weight of a medicament structure is reduced, and the metabolism velocity of a radioactive medicament in a non-target organ is increased. The three radioactive medicaments include 99mTc-HYNIC-K(NIC)-RGD2, 99mTc-HYNIC-K(NIC)-3G-RGD2 and 99mTc-HYNIC-K(NIC)-3P-RGD2, and are colorless and transparent liquid injections. |
priorityDate | 2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.